GLMD Galmed Pharmaceuticals
- 0.3839
- -0.0198-4.90%
- 0.4073
- +0.0234+6.10%
Galmed Pharmaceuticals News
Hepion Ends Phase 2 Study for NASH Drug Due to Cash Restraints
Why PriceSmart Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket
Shares of PriceSmart, Inc. (NASDAQ:PSMT) rose sharply in today's pre-market trading as the company posted better-than-expected earnings for its second quarter. The company reported quarterly earnings
Madrigal Announces US Launch of NASH/MASH Drug Rezdiffra
Why Agenus Shares Are Trading Lower By Around 17%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Agenus Inc. (NASDAQ:AGEN) fell sharply during Monday's session. Agenus disclosed a 1-for-20 reverse stock split of common stock. Agenus Inc. (NASDAQ:AGEN) declined 17% to $0.4181 on Monday.
Why Esperion Therapeutics Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) shares rose sharply during today's pre-market trading after the company presented new data from CLEAR outcomes at ACC.24 highlighting value of NEX
Galmed Pharmaceuticals Ltd. (GLMD) Surges After Hours: An Unexpected Rally
Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) concluded its Friday's trading session with a modest 2.8% gain, leaving investors to be cautiously optimistic. However, the post-closing activity took an unforeseen turn, with GLMD experiencing a remarkable 15% surge in after-hours trading. During the typically quieter after-hours session, GLMD's stock surged, capturing investors' attention. Trading volume spiked to ...
Galmed Pharmaceuticals Granted Nasdaq Extension
On March 19, Galmed Pharmaceuticals Got Letter From Nasdaq That Granted Co Additional 180 Calendar Day Period To Regain Compliance
On March 19, Galmed Pharmaceuticals Got Letter From Nasdaq That Granted Co Additional 180 Calendar Day Period To Regain Compliance
Inventiva Phase 2 Study for MASH Drug Meets Primary Endpoint
The NASH pharmaceutical market is expected to exceed $48 billion by 2035, and companies such as Novo Nordisk (NVO.US) and Lily.US (LLY.US) will begin to deploy
According to international consulting firm Research Nester, the global non-alcoholic steatohepatitis (NASH) treatment market is expected to reach US$48.3 billion by 2035.
NASH Drug Market Expected to Surpass $48B by 2035
Express News | Galmed Announces Grant Of New Patent For Combination Of Aramchol With Resmetirom (MGL-3196, REZDIFFRA) For Treatment Of NASH And Liver Fibrosis
Sector Update: Health Care Stocks Higher Late Tuesday Afternoon
Health care stocks advanced late Tuesday afternoon, with the NYSE Health Care Index adding 0.7% and the Health Care Select Sector SPDR Fund (XLV) up 0.6%. The iShares Biotechnology ETF (IBB) fell 0.7%
Sector Update: Health Care
Health care stocks advanced late Tuesday afternoon with the NYSE Health Care Index adding 0.7% and the Health Care Select Sector SPDR Fund (XLV) up 0.6%. The iShares Biotechnology ETF (IBB) fell 0.7%.
Galmed Announces a Delay in the Initiation of Its Primary Sclerosing Cholangitis (PSC) Phase 2a Study
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) announced today a delay of at least 6 months in the initiation of its Primary Sclerosing Cholangitis (PSC) Ph 2a Study.
Galmed Pharmaceuticals Has Been Granted European Patent Number EP3538158 Titled "Treatment For Fibrosis (Including Methods For Inhibition Of Fibrotic Disorders And Hepato-Fibrotic Conditions Associated With NAFLD And NASH)"
Galmed Pharmaceuticals Has Been Granted European Patent Number EP3538158 Titled "Treatment For Fibrosis (Including Methods For Inhibition Of Fibrotic Disorders And Hepato-Fibrotic Conditions Associate
Galmed Announces Allowance Of New Patent For Aramchol For The Treatment Of Pulmonary And Dermal Fibrosis
Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic diseases announced today the allowance of a Japanese
Galmed Pharmaceuticals Announces Receipt Of Nasdaq Minimum Bid Price Notification
Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic diseases, today announced that the Company received
Drugmakers Still Chasing Potentially Lucrative NASH Market, Despite Setbacks
Stocks That Hit 52-Week Lows On Thursday
 During Thursday's session, 92 stocks hit new 52-week lows. Intriguing Points From Today's 52-Week Lows: Pfizer (NYSE:PFE) was the biggest company on a market cap basis to set a new 52-week low.Bit
Analysis
Price Target
No Data
